A5006667126- Helicobacter pylori-related gastroenterology studies
- Eosinophilic Esophagitis
- Liver Disease Diagnosis and Treatment
- Gastroesophageal reflux and treatments
- Hepatitis C virus research
- Endoplasmic Reticulum Stress and Disease
- Liver physiology and pathology
- Gastrointestinal disorders and treatments
- Gastric Cancer Management and Outcomes
- Respiratory and Cough-Related Research
- Veterinary medicine and infectious diseases
- Hepatitis B Virus Studies
Shanghai Jiao Tong University
2018-2024
Shanghai First People's Hospital
2024
Renji Hospital
2018-2019
Research Triangle Park Foundation
2014
GlaxoSmithKline (United States)
2014
Abstract Background A reliably highly effective high‐dose proton‐pump inhibitor plus amoxicillin (dual Helicobacter pylori therapy) has remained elusive. We compared whether the addition of bismuth to dual therapy would improve efficacy as first‐line treatment. Methods This was an open‐label, randomized single‐center study 160 treatment‐naive patients with H. infection who were randomly assigned 14‐day esomeprazole 40 mg twice a day 1 g three times or without potassium citrate 600 (elemental...
Abstract Background and Aim Hydronidone (HDD) is a novel pirfenidone derivative developed initially to reduce hepatotoxicity. Our previous studies in animals humans have demonstrated that HDD treatment effectively attenuates liver fibrosis, yet the underlying mechanism remains unclear. This study aimed investigate whether exerts its anti‐fibrotic effect by inducing apoptosis activated hepatic stellate cells (aHSCs) through endoplasmic reticulum stress (ERS)‐associated mitochondrial apoptotic...
Abstract Background Helicobacter pylori ( H. ) eradication has become increasingly difficult especially for penicillin allergy patients. Aims To evaluate the efficacy of adding bismuth or high‐dose metronidazole to an regimen containing a proton‐pump inhibitor, clarithromycin, and in patients allergic penicillin. Methods Pilot study which penicillin‐allergic, treatment‐naive subjects were randomized (1:1) 14‐day esomeprazole (20 mg q12h), clarithromycin (500 high dose (400 q6h) with BECM...
The high prevalence of Helicobacter pylori (H pylori) infection in China results a substantial public health burden. Medical experts have not agreed on the best solution population intervention for this problem. We presented economic evaluation population-based H screen-and-treat strategy preventing gastric cancer, peptic ulcer disease (PUD), and nonulcer dyspepsia (NUD).Decision trees Markov models were developed to evaluate cost-effectiveness screening followed by eradication treatment...
Abstract This first‐time‐in‐human, randomized, double‐blind, placebo‐controlled, dose‐escalation study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of GSK2485852, a hepatitis C virus (HCV) NS5B inhibitor, in 27 chronically infected HCV genotype‐1 subjects. Subjects received GSK2485852 70, 420, 70 mg with moderate fat/caloric meal. Safety, activity, genotype/phenotype, interleukin 28B genotype were evaluated. A statistically significant reduction ribonucleic...
Summary Background: Susceptibility-guided therapy is the best method for treating infectious diseases. However, it remains uncertain whether this could be applied Helicobacter pylori (H. pylori) infection in patients with treatment failures. We evaluated efficacy and tolerability of culture susceptibility-guided as rescue treatment.
Background: A reliably highly effective high-dose proton pump inhibitor plus amoxicillin (dual Helicobacter pylori therapy) has remained elusive. We compared whether the addition of bismuth to highdose dual therapy would improve efficacy as first-line treatment. Methods: This was an open-label, randomized single-center study 160 treatment-naive patients with infection who were randomly assigned 14-day esomeprazole 40 mg twice a day 1 g three times or without 600 day. Antibiotic resistance...